Evidence map›Paper›PMID 38005887›Full record

ArticleViruses2023

Epidemiological and Genomic Analysis of Asymptomatic SARS-CoV-2 Infections during the Delta and Omicron Epidemic Waves in São Paulo City, Brazil.

Svetoslav N Slavov, Alex R J Lima, Gabriela Ribeiro, Loyze P O de Lima, Claudia R Dos S Barros, Elaine C Marqueze, Antonio J Martins, Maiara Martininghi, Melissa Palmieri, Luiz A V Caldeira and 8 more

Abstract read
In one paragraph

Article in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Svetoslav N SlavovCenter for Viral Surveillance and Serological Assessment (CeVIVAS), Butantan Institute, São Paulo 05507-000, SP, Brazil.ORCID 0000-0003-0805-6140
Alex R J LimaCenter for Viral Surveillance and Serological Assessment (CeVIVAS), Butantan Institute, São Paulo 05507-000, SP, Brazil.
Gabriela RibeiroCenter for Viral Surveillance and Serological Assessment (CeVIVAS), Butantan Institute, São Paulo 05507-000, SP, Brazil.
Loyze P O de LimaCenter for Viral Surveillance and Serological Assessment (CeVIVAS), Butantan Institute, São Paulo 05507-000, SP, Brazil.
Claudia R Dos S BarrosCenter for Viral Surveillance and Serological Assessment (CeVIVAS), Butantan Institute, São Paulo 05507-000, SP, Brazil.
Elaine C MarquezeCenter for Viral Surveillance and Serological Assessment (CeVIVAS), Butantan Institute, São Paulo 05507-000, SP, Brazil.ORCID 0000-0002-4987-7757
Antonio J MartinsCenter for Viral Surveillance and Serological Assessment (CeVIVAS), Butantan Institute, São Paulo 05507-000, SP, Brazil.
Maiara MartininghiHealth Surveillance Coordination, Municipal Health Department of São Paulo, Coordenadoria de Vigilância em Saúde (COVISA), Secretaria Municipal de São Paulo (SMS SP), São Paulo 01223-010, SP, Brazil.
Melissa PalmieriHealth Surveillance Coordination, Municipal Health Department of São Paulo, Coordenadoria de Vigilância em Saúde (COVISA), Secretaria Municipal de São Paulo (SMS SP), São Paulo 01223-010, SP, Brazil.
Luiz A V CaldeiraHealth Surveillance Coordination, Municipal Health Department of São Paulo, Coordenadoria de Vigilância em Saúde (COVISA), Secretaria Municipal de São Paulo (SMS SP), São Paulo 01223-010, SP, Brazil.
Fabiana E V da SilvaPrimary Care Coordination Municipal Health Department of São Paulo, Coordenadoria de Atenção Básica, Secretaria Municipal de São Paulo (SMS SP), São Paulo 01223-010, SP, Brazil.
Giselle CacherikPrimary Care Coordination Municipal Health Department of São Paulo, Coordenadoria de Atenção Básica, Secretaria Municipal de São Paulo (SMS SP), São Paulo 01223-010, SP, Brazil.
Aline L NicolodelliPrimary Care Coordination Municipal Health Department of São Paulo, Coordenadoria de Atenção Básica, Secretaria Municipal de São Paulo (SMS SP), São Paulo 01223-010, SP, Brazil.
Simone KashimaRibeirão Preto Medical School, Ribeirão Preto 14051-140, SP, Brazil.
Marta GiovanettiInstitute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte 31270-901, MG, Brazil.ORCID 0000-0002-5849-7326
Luiz Carlos Junior AlcantaraInstitute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte 31270-901, MG, Brazil.ORCID 0000-0002-6769-9931
Sandra C SampaioCenter for Viral Surveillance and Serological Assessment (CeVIVAS), Butantan Institute, São Paulo 05507-000, SP, Brazil.
Maria C EliasCenter for Viral Surveillance and Serological Assessment (CeVIVAS), Butantan Institute, São Paulo 05507-000, SP, Brazil.ORCID 0000-0002-0501-8280

Funding

University of Washington Arboviral Research Network (UWARN)U01AI151698 · NIAID · UNIVERSITY OF WASHINGTON · PI Michael Gale, PETER MACGARR RABINOWITZ · 2020 to 2026
$13.3M
NIAID NIH HHS U01 AI151698
6 · The paper itself

Abstract

We examined the asymptomatic rates of SARS-CoV-2 infection during the Delta and Omicron waves in the city of São Paulo. Nasopharyngeal swabs were collected at strategic points of the city (open-air markets, bus terminals, airports) for SARS-CoV-2 RNA testing. Applying the questionnaire, the symptomatic individuals were excluded, and only asymptomatic cases were analyzed. During the Delta wave, a total of 4315 samples were collected, whereas 2372 samples were collected during the first Omicron wave. The incidence of the asymptomatic SARS-CoV-2 infection was 0.6% during the Delta wave and 0.8% during the Omicron wave. No statistical differences were found in the threshold amplification cycle. However, there was a statistical difference observed in the sublineage distribution between asymptomatic and symptomatic individuals. Our study determined the incidence of asymptomatic infection by monitoring individuals who remained symptom-free, thereby providing a reliable evaluation of asymptomatic SARS-CoV-2 carriage. Our findings reveal a relatively low proportion of asymptomatic cases, which could be attributed to our rigorous monitoring protocol for the presence of clinical symptoms. Investigating asymptomatic infection rates is crucial to develop and implement effective disease control strategies.

Indexed as

COVID-19Asymptomatic InfectionsBrazilGenomicsHumansRNA, ViralSARS-CoV-2RNA, Viralasymptomatic infectionBrazilepidemiologygenomic surveillancemolecular testingSARS-CoV-2

Identifiers

PMID38005887
PMCPMC10675288

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.